Novartis presents updated data that reinforce the efficacy and safety of Kisqali ® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer

Novartis announced today updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news